Local peritoneal toxicity from adjuvant pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in high-risk patients with colonic cancer.
暂无分享,去创建一个
[1] J. Raoul,et al. A phase I dose-escalation study of oxaliplatin delivered via a laparoscopic approach using pressurised intraperitoneal aerosol chemotherapy for advanced peritoneal metastases of gastrointestinal tract cancers. , 2020, European journal of cancer.
[2] M. Hübner,et al. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. , 2019, The Lancet. Oncology.
[3] S. Detlefsen,et al. Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in resected high-risk colon cancer patients – study protocol for the PIPAC-OPC3 Trial. A prospective, controlled phase 2 Study , 2018, Pleura and peritoneum.
[4] S. Detlefsen,et al. University of Southern Denmark Prospective , single-center implementation and response evaluation of pressurized intraperitoneal aerosol chemotherapy ( PIPAC ) for peritoneal metastasis , 2018 .
[5] N. Demartines,et al. Systematic review of pressurized intraperitoneal aerosol chemotherapy for the treatment of advanced peritoneal carcinomatosis , 2017, The British journal of surgery.